Safety and efficacy evaluation of Mirvaso gel 0.33 % (brimonidine tartrate) by Post marketing surveillance

Study identification

• EU PAS number:
  EUPAS17600
• Study ID:
  18044
• Official title and acronym:
  Safety and efficacy evaluation of Mirvaso gel 0.33 % (brimonidine tartrate) by Post marketing surveillance
• DARWIN EU® study:
  No
• Study countries:
  Korea, Republic of
• Study status:
  Ongoing

Research institutions and networks

Institutions

Galderma Korea

Study timelines

Date when funding contract was signed

Planned:15/09/2016

Actual:15/09/2016

Study start date

Planned:15/12/2016

Actual:15/12/2016

Data analysis start date

Planned:15/09/2017

Date of interim report, if expected

Planned:15/11/2017

Date of final study report

Planned:15/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Galderma Korea Ltd

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable